Health
Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy – News-Medical.net
The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice….
A team of scientists from the United States has recently developed a formulation of toll-like receptor 9 (TLR9) agonist and aluminum hydroxide to increase the immunogenicity of spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice. The study is currently available on the bioRxiv* preprint server.
…
-
Noosa News13 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News20 hours agoDifficult to diagnose and potentially deadly — this lesser-known disease is becoming more common
-
Noosa News21 hours agoCountdown on for Noosa Eat & Drink Festival 2025
-
Noosa News18 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up